[10]
Lodish HF. Molecular Cell Biology. 4th ed. W.H. Freeman: New York, USA 2000.
[28]
Wang S, Ding K, Lu Y, et al. Small molecule inhibitors of MDM2 and uses thereof WO2006091646. (2006).
[30]
Shangary S, Qin D, McEachern D, Miller R, Nikolovska-Coleska Z, Liu M, et al. A novel orally active MDM2 inhibitor (MI-219) activates the 53.AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. San Francisco, USA October 2007.
[36]
Bartkovitz DJ, Chu XJ, Ding Q, et al. Spiroindolinone pyrrolidines US20100939234. (2010).
[46]
Bartberger MD, Gonzalez Buenrostro A, Beck H P. Chen, X.,
Connors, R.V., Deignan, J., Duquette, J., Eksterowicz, J., Fisher,
B., Fox, B.M., Fu, J., Fu, Z., Gonzalez Lopez De Turiso, F., Gribble,
Jr., M.W., Gustin, D.J., Heath, J.A., Huang, X., Jiao, X., Johnson,
M., Kayser, F., Kopecky, D.J., Lai, S., Li, Y. Li, Z., Liu, J.,
Low, J.D., Lucas, B.S., Ma, Z., McGee, L., McIntosh, J., McMinn,
D., Medina, J.C., Mihalic, J.T., Olson, S.H., Rew, Y., Roveto,
P.M., Sun, D., Wang, X., Wang, Y., Yan, X., Yu, M., Zhu, J. Piperidinone Derivatives as MDM2 inhibitors for the treatment of
cancer WO2011153509. (2011).
[50]
Uoto K, Sugimoto Y, Naito H, Miyazaki M, Yoshida K, Aonuma M. Imidazothiazole derivative having proline ring structure WO2010082612. (2010).
[51]
Sugimoto Y, Uoto K, Miyazaki M, et al. Dispiropyrrolidine
derivative WO2012121361. (2012).
[52]
Berghausen J, Buschmann N, Furet P, et al. Substituted isoquinolinones and
quinazolinones WO2011076786. (2011).
[55]
Wu CE, Esfandiari A, Ho YH, Shepherd C, Mahdi AK, Aptullahoglu E, et al. Abstract 2151: Inhibition of WIP1/PPM1D phosphatase by GSK2830371 potentiates the growth inhibitory and cytotoxic activity of MDM2 antagonists (nutlin-3, RG7388 and HDM201) in cutaneous melanoma cells.AACR Annual Meeting 2017. Washington, DC, USA April, 2017.
[57]
Rudolph D, Gollner A, Blake S, Rinnenthal J, Wernitznig A, Weyer-Czernilofsky U, et al. BI 907828: A novel, potent MDM2 inhibitor that is suitable for high-dose intermittent schedules.AACR Annual Meeting 2018. Chicago, USA 2018.
[60]
Bartkovitz DJ, Chu XJ, Vu BT, Zhao C, Fishlock D. Substituted pyrrolidine-2-carboxamides US8993614. (2015).
[61]
Bartkovitz DJ, Chu XJ, Ehrlich GK, et al. Substituted pyrrolidine-2-carboxamides US9371280. (2016).
[62]
Higgins B, Tovar C, Glen K, Railkar A, Filipovic Z, Qureshi F, et al. Preclinical activity of MDM2 antagonist RO6839921, a pegylated prodrug for intravenous administration.AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. Boston, MA, USA November 2015.
[65]
Yee K, Uy G, Assouline S, Britten CD, Zhi J, Blotner S, et al. A phase I study of the MDM2 antagonist RO6839921, a pegylated intravenous prodrug of idasanutlin, in patients with AML. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Philadelphia, USA (2017). Eur J Cancer 2016; 69(1): S21-2.
[66]
Higgins B, Kolinsky K, Nichols G, Packman K, Su F. Combination therapy for proliferative disorders US20130245039. (2013).
[67]
Higgins B, Kolinsky K, Nichols G, Packman K, Su F. Combination
therapy for proliferative disorders US9216170. (2015).
[68]
Chu X-J, Lovey AJ, Vu BT, Zhao C. Novel imidazolines as
dual inhibitors of MDM2 and MDMX WO2014082889. (2014).
[69]
Higgins B, Nichols G, Packman K. Combination of Ro5503781
and capecitabine for cancer therapy WO2014202492. (2014).
[70]
Higgins B, Nichols G, Packman K. Combination of Ro5503781,
capecitabine and oxaliplantin for cancer therapy WO2014202497. (2014).
[71]
Higgins B, Nichols G, Packman K. Combination treatment for
acute myeloid leukemia (AML) US20150157603. (2015).
[72]
Higgins B, Nichols G, Packman K. Combination treatment for
acute myeloid leukemia (AML) US9956243. (2018).
[73]
Klein C, Herting F, Dangl M. Combination therapy of an anti
CD20 antibody with a Bcl-2 inhibitor and a MDM2 inhibitor WO2016188935. (2016).
[74]
Blotner SD, Chen G, Jukofsky L, et al. Methods for personalizing patient
cancer therapy with an MDM2 antagonist WO2016055497. (2016).
[75]
Wang S, Sun W, Aguilar A, Garcia-Echeverria C. Spirooxindole
MDM2 antagonists WO2012155066. (2012).
[76]
Wang S, Aguilar A, Liu L, Lu J, McEachern D. MDM2 inhibitors
and therapeutic methods using the same WO2015161032. (2015).
[77]
Bartberger MD, Beck HP, Chen X, et al. Heterocyclic compounds as MDM2 inhibitors
for the treatment of cancer WO2013049250. (2013).
[79]
Bartberger MD, Beck HP, Degraffenreid MR, et al. Cismorpholinone
and other compounds as MDM2 inhibitors for the
treatment of cancer WO2014130470. (2014).
[80]
Gonzalez Buenrostro A, Li Y, Medina J, Olson S. Heteroaryl
acid morpholinone compounds as MDM2 inhibitors for the treatment
of cancer WO2014151863. (2014).
[82]
Rew Y. Benzoic acid derivative MDM2 inhibitor for the treatment
of cancer US20140243372. (2014).
[84]
Bio M, Caille S, Cochran B, Fang Y, Vounatsos F, Wortman S. Processes of making and crystalline forms of A MDM2 inhibitor US20140364455. (2014).
[85]
Bio M, Caille S, Cochran B, Fang Y, Vounatsos F, Wortman S. Processes of making and crystalline forms of a MDM2 inhibitor US9376386. (2016).
[87]
Caenepeel S, Canon J, Hughes P, Oliner JD, Saiki AY, Rickles RJ. Combination therapy including an MDM2 inhibitor
and one or more additional pharmaceutically active agents for the
treatment of cancers US20160287569. (2016).
[89]
Gollner A, Kofink C, Ramharter J, Weinstabl H, Wunberg T. Spiro[3h-indole-3,2’-pyrrolidin]-2(1h)-one derivatives and their
use as MDM2-p53 inhibitors WO2015155332. (2015).
[90]
Gollner A, Kofink C, Ramharter J, Weinstabl H, Wunberg T. Spiro[3H-indole-3,2’-pyrrolidin]-2(1H)-one compounds and derivatives
as MDM2-P53 inhibitors US10138251. (2018).
[91]
Ramharter J, Broeker J, Gille A, et al. New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one
compounds and derivatives as MDM2-p53 inhibitors WO2016026937. (2016).
[92]
Gollner A, Broeker J, Kerres N, et al. Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives
as MDM2-p53 inhibitors WO2017060431. (2017).
[94]
Rinnenthal J, Rudolph D, Blake S, Gollner A, Wernitznig A, Weyer-Czernilofsky U, et al. BI 907828: A highly potent MDM2
inhibitor with low human dose estimation, designed for high-dose
intermittent schedules in the clinic.AACR Annual Meeting 2018. Chicago, USA (2018).
[95]
Rudolph D, Reschke M. Anticancer combination therapy WO2018185135. (2018).
[97]
Nakamaru K, Seki T, Tazaki K, Tse A. Abstract B5: Preclinical
characterization of a novel orally-available MDM2 inhibitor DS-
3032b: Anti-tumor profile and predictive biomarkers for sensitivity.AACR-NCI-EORTC International Conference: Molecular Targets
and Cancer Therapeutics. Boston, USA December, 2015.
[99]
Yoshida S, Sugimoto Y. Crystal of Dispiropyrrolidine derivative WO2014038606. (2014).
[100]
Tse NA, Nakamaru K, Tazaki K, Watanabe K, Seki T. Gene
signatures associated with sensitivity to MDM2 inhibitors WO2015108175. (2015).
[101]
Tse NA, Nakamaru K, Tazaki K, Watanabe K, Seki T. Algorithms
for gene signature-based predictor of sensitivity to MDM2
inhibitors WO2016056673. (2016).
[102]
Seki T. Combination method for treating cancer WO2016133194. (2016).
[103]
Seki T. Treatment method combining mdm2 inhibitor and BTK
inhibitor WO2016167236. (2016).
[104]
Seki T. Combination therapy method using MDM2 inhibitor and
DNA methyltransferase inhibitor WO2018074387. (2018).
[105]
Furet P, Guagnano V, Holzer P, et al. Pyrazolopyrrolidine compounds WO2013080141. (2013).
[106]
Furet P, Guagnano V, Holzer P, et al. Imidazopyrrolidinone
compounds WO2013111105. (2013).
[107]
Cotesta S, Furet P, Guagnano V, et al. Pyrrolopyrrolidinone
compounds WO2013175417. (2013).
[108]
Furet P, Guagnano V, Holzer P, et al. Substituted purinone compounds WO2014115077. (2014).
[109]
Furet P, Guagnano V, Holzer P, et al. Pyrazolo[3,4-d]pyrimidinone compounds
as inhibitors of the P53/MDM2 interaction WO2014115080. (2014).
[110]
Emerson E, Halilovic E, Wang H-Q, Zubrowski M. Combination
of MDM2 inhibitor and BRAF inhibitor and their use WO2015084804. (2015).
[111]
Ferretti S, Jeay S, Halilovic E, Li F, Wang H. Pharmaceutical
combinations WO2015097622. (2015).
[112]
Li F, Wang H, Halilovic E, Liang J. Pharmaceutical combinations WO2015097621. (2015).
[113]
Ferretti S, Jeay S. Intermittent dosing of MDM2 inhibitor WO2015198266. (2015).
[114]
Bhatia R. Pharmaceutical combinations and their use WO2016035023. (2016).
[115]
Guerreiro N, Meille C, Wuerthner J. Gdf-15 as a haematological
toxicity biomarker WO2017021908. (2017).
[116]
Halilovic E, Emery C. MDM2 inhibitors for treating uveal melanoma WO2017029588. (2017).
[117]
Halilovic E, Caponigro G, Horn-Spirohn T, Lehar J. MDM2
inhibitors and combinations thereof WO2017037579. (2017).
[118]
Caponigro G, Horn-Spirohn T, Lehar J. Combination therapy
using Pi3k inhbitor and MDM2 inhibitor WO2017037586. (2017).
[119]
Chapeau E, Durand E, Gembarska A, Jensen MR, Mandon E. Combinations of MDM2 inhibitors and Bcl-xl inhibitors WO2018092064. (2018).
[120]
Halilovic E, Wang Y. Combination of a Bcl-2 inhibitor and a
Mdm2 inhibitor, uses and pharmaceutical compositions thereof WO2018158225. (2018).
[121]
Wang H, Ye J, Han B, et al. Chemical process for preparing
imidazopyrrolidinone derivatives and intermediates thereof WO2018096440. (2018).
[122]
Ihry R, Kaykas A, Worringer K. Methods and compositions for
enhancing gene editing WO2018083606. (2018).
[125]
Ricci CG, Chen JS, Miao Y, Jinek M, Doudna JA, McCammon JA, et al. Molecular mechanism of off-target effects in CRISPR-Cas9 bioRxivorg. 2018.
[126]
Ferretti S, Guerreiro N, Jeay S, Jullion A, Meille C, Wuerthner J. Dose and regimen for HDM2-p53 interaction inhibitors WO2018092020. (2018).
[127]
Ferretti S, Guerreiro N, Jeay S, Jullion A, Meille C, Wuerthner J. Dose and regimen for an HDM2-p53 interaction inhibitor
in hematological tumors WO2018178925. (2018).
[128]
Cooke V, Visser M S, Wylie A, Yerramilli-Rao P, Zhu X. Protein kinase C inhibitors for treatment of uveal melanoma WO201905359. (2019).
[129]
Caponigro G, Halilovic E, Monaco KA. Combinations of
MDM2 inhibitors with inhibitors of ERK for treating cancers WO2019073435. (2019).
[130]
Inga A, De Magalhães Pinto MM, Ataíde Saraiva LH, et al. Inhibitors of p53-
MDM2 interaction WO2013105037. (2013).
[132]
Errico JP, Mugrage B, Turchi I, et al. Combination therapy with MDM2 and EFGR inhibitors US8658170. (2014).
[133]
Wannian Z, Zhenyuan M, Chunlin Z, et al. Pyrrolidone pyrazole compound
and purposes thereof as drugs CN103819476. (2014).
[134]
Wannian Z, Zhenyuan M, Chunlin Z, et al. Pyrrolidone pyrazole compound
and purposes thereof as drugs CN103819476. (2016).
[135]
Feder M, Dubin G, Bulkowska U, et al. 1,5-Dihydropyrrol-2-one derivatives
as inhibitors of p53-MDM2/MDM4 protein-protein interaction WO2015004610. (2015).
[136]
Feder M, Kalinowska I, Jaszczewska JA, et al. Compounds
comprising 1,1ʹ,2,5ʹ-tetrahydrospiro[indole-3,2ʹ-pyrrole]-2,5ʹ-
dione system as inhibitors p53-MDM2 protein-protein interaction wo2015189799. (2015).
[137]
Park HG, Park YH, Lee HJ. α-alkyl-α-carbonyl lactam derivatives
and their stereoisomers, and pharmaceutical composition containing
the same KR101497962. (2015).
[138]
Arora PS, Lao B, Guarracino D, Bonneau R, Drew K. Oxopiperazine helix mimetics as inhibitors of the p53-MDM2 interaction WO2015160914. (2015).
[139]
Chen Y, Ding Q, Sun Y. Spiropyrrolidines as MDM2 inhibitors US9701685. (2017).
[140]
Su Z, Zhang H, Chen Y, Wang W. Small-molecule inhibitor of
MDM/MDM<2>, as well as preparation method and applications CN103923067. (2016).
[141]
Chessari G, Howard S, Buck IM, et al. Isoindolinone
inhibitors of the MDM2-p53 interaction having anticancer activity WO2017055859. (2017).
[142]
Howard S, Cons BD, St. Denis JD, Griffiths-Jones CM, Hiscock SD, Holvey RS. Burns, A.R., Cousin, D., Dexter, H.L.,
Parra, G.F., Watts, J.P., Jewell, R., Stockwell, J.A., Hirst, K.L.,
Lemasson, I.A., Nash, David, J., Osborne, J.D., Priede, J.C., Richards,
N.P., Dumas, A.M., Bishop, B.C., Parry-Jones, D., Scott, J.P.,
Shaunmugham, M.S., Mullens, P.R., Lathbury, D.C., Dixon, D.J.,
Gaunt, M.J Isoindolinone inhibitors of the MDM2-p53 interaction
and process for making them WO2018178691. (2018).
[143]
Xiao F, Ma J, Xiao F, et al. Spirocyclic indolone polyethylene glycol
carbonate compound, composition, preparation method and use
thereof WO2018027477. (2018).
[144]
Barakat A, Islam MS, Al Majid AM, et al. Substituted spirooxindoles US9822128. (2017).
[145]
Mazhuga AG, Beloglazkina EK, Ivanenkov YA, Beloglazkina AA, Kukushkin ME, Barashkin AA. Method of obtaining
dispiroindolinones RU2682678. (2019).
[146]
Fletcher S, Drennen B, Conlon I, Lanning M. Dual inhibitors
of the Bcl-2 and HDM2 families through co-mimicry of the BH3
and p53-alpha-helices WO2019040511. (2019).
[147]
Yin L, Yao Z, Li H. Compound capable of being used as tumor
inhibitor, preparation method therefor, and application thereof WO2019128877. (2019).
[148]
Feder M, Mazur M, Kalinowska I, et al. 1,2,3',5'-
tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione
compounds as therapeutic agents activating Tp53 WO2019141549. (2019).
[149]
Rossello A, Nuti E, Orlandini E, et al. Compounds with a
benzo[a]carbazole structure and use thereof WO2019049024. (2019).
[150]
Nair H, Santhamma B, Nickisch K. Novel cytotoxic agents that
preferentially Target Leukemia Inhibitory Factor (LIF) for the
treatment of malignancies and as new contraceptive agents WO2016154203. (2016).
[151]
Crew AP, Crews CM, Dong H, Qian Y, Wang J. MDM2-
based modulators of proteolysis and associated methods of use US2017008904. (2017).
[152]
Xia J, Xun H, Wang Y, Zhou Z, Gao Q, Zheng B. Synthetic
method for p53-MDM2-binding inhibitor dyhydroxyl quinoline derivative CN105017219. (2017).
[153]
Kim HY, Cho ML, Jhun JY, Byun JK. Composition for
inhibiting aging comprising MDM2 inhibitor KR20130139512. (2013).
[154]
Oda K, Makii C. Ovarian clear cell adenocarcinoma therapeutic
agent JP2018012666. (2018).
[155]
Nathanson D-A, Mai WX, Jung M-E, et al. Compositions and methods
for treating cancer US2018052858. (2018).
[156]
Balko J-M, Johnson DB, de Delgado VS, Sanders M. Methods
and systems for predicting response to immunotherapies for
treatment of cancer US2019284640. (2019).
[157]
Shetty S, Idell S. Inhibition of pulmonary fibrosis with nutlin-3a
and peptides WO2014145389. (2014).
[159]
Zhao X, Li Y. Methods for treating cognitive deficits associated
with fragile X syndrome US2017079977. (2017).
[161]
David N. Compounds and therapeutic uses US2017281649. (2017).
[162]
Laberge RM, Campisi J, Davalos A, et al. Methods and compositions for killing senescent cells and for treating
senescence-associated diseases and disorders WO2015116740. (2015).
[163]
Lopez-Dominguez JA, Laberge RM, Campisi J, et al. Compositions
and methods for treating senescence-associated diseases
and disorders US2018193458. (2018).
[164]
Hopkins J, Tsuruda P, Chapman C, et al. Treatment
of ophthalmic conditions such as macular degeneration, glaucoma,
and diabetic retinopathy using pharmaceutical agents that eliminate
senescent cells WO2019033119. (2019).
[165]
Chinta S-J, Campisi J, Andersen JK, et al. Treatment of Parkinson's
disease and other conditions caused or mediated by senescent astrocytes
using small molecule senolytic agents US2019269675. (2019).
[173]
Singavi AK, Menon S, Kilari D, Alqwasmi A, Ritch PS, Thomas JP, et al. 1140PD: Predictive biomarkers for hyper-progression
(HP) in response to immune checkpoint inhibitors (ICI)-analysis of
somatic alterations (SAs).ESMO 2017 Congress. Madrid, Spain September, 2017.
[174]
Wang HQ, Liang J, Mulford I, Sharp F, Gaulis S, Chen Y, et al. Abstract 5560: PD-1/PD-L1 blockade enhances MDM2 inhibitor
activity in p53 wild-type cancers. AACR Annual Meeting 2018. Chicago, IL, USA April, 2018.
[175]
Goyama S, Hayashi Y, Liu X, Shikata S, Tanaka Y, Fukuyama T, et al. A p53-MDM2 interaction inhibitor, DS-5272, inhibits the development
of MLL-fusion leukemia with the assistance of tumor
immunity. ASH 2017-59th American Society of Hematology Annual
Meeting and Exposition. Atlanta, USA December, 2017.
[176]
Rudolph D, Reschke M, Blake S, Rinnenthal J, Wernitznig A, Weyer-Czernilofsky U, et al. BI 907828: A novel, potent MDM2
inhibitor that induces antitumor immunologic memory and acts
synergistically with an anti-PD-1 antibody in syngeneic mouse
models of cancer.AACR Annual Meeting 2018. Chicago, IL, USA April, 2018.
[178]
Martinelli G, Pappayannidis C, Yee K, Vey N, Drummond M, Kelly K, et al. Phase 1b results of idasanutlin + cytarabine (ara-c)
in Acute Myeloid Leukemia (AML) patients (Pts).21st Congress of
the European Hematology Association. Copenhagen, Denmark. June, 2016.
[187]
Daver N. Safety, efficacy, pharmacokinetic (PK) and biomarker
analyses of Bcl2 inhibitor Venetoclax (Ven) plus MDM2 inhibitor
idasanutlin (idasa) in patients (pts) with Relapsed or Refractory
(R/R) AML: A Phase Ib, non-randomized, open-label study.ASH
2018-60th American Society of Hematology Annual Meeting and
Exposition. San Diego, USA (2018).
[189]
Roxburgh P, Currie D, Morrison P, Kelly C, Thomson F, McCormick C, et al. Abstract CT027: Safety, pharmacokinetics (PK) &
pharmacodynamics (PD) of idasanutlin (idasa), combined with abiraterone
(abi)/prednisolone (pred) or enzalutamide (enza) in castrate
resistant prostate cancer (CRPC).AACR Annual Meeting
2018. Chicago, IL, USA April, 2018.
[199]
Scott M, Clarke C, Warren F, Drotar M, Jorgensen H, Hyde R, et al. The combination of the MDM2 antagonist, idasanutlin with nilotinib targets primitive chronic myeloid leukemia (CML) cells in vitro and in vivo. In: 23rd Congress of the European Hematology Association. Stockholm, Sweden June, 2018.
[201]
Chawla SP, Blay JY, Italiano A, Gutierrez M, Le Cesne A, Gomez-Roca CA, et al. Phase Ib study of RG7112 with doxorubicin (D) in advanced soft tissue sarcoma (ASTS). J Clin Oncol 2013; 31: 10514.
[206]
Latif AL, Cole JJ, Monteiro Campos J, Clark W, McGarry L, Brock C, et al. Abstract 647: Dual inhibition of MDM2 and BET
cooperate to eradicate acute myeloid leukemia.ASH 2015-57th
American Society of Hematology Annual Meeting and Exposition. Orlando, USA (2015).
[212]
Caenepeel S, Canon J, Hughes P, Oliner JD, Rickles RJ, Saiki AY. Combination therapy including an MDM2 inhibitor and
one or more additional pharmaceutically active agents for the
treatment of cancers. WO2015070224. (2015).
[229]
DiNardo CD, Rosenthal J, Andreeff M, Zernovak O, Kumar P, Gajee R, et al. Phase 1 dose escalation study of MDM2 inhibitor DS-3032b in patients with hematological malignancies-preliminary results. Blood 2016; 128(22): 593-3.
[231]
Andreeff M, Zhang W, Kumar P, Zernovak O, Daver NG, Isoyama T. Synergistic anti-leukemic activity with combination of FLT3 inhibitor uizartinib and MDM2 inhibitor milademetan in FLT3-ITD
mutant/p53 wild-type acute myeloid leukemia models.ASH 2018-
60th American Society of Hematology Annual Meeting and Exposition. San Diego, USA 2018.
[235]
Fang DD, Zhai G, Xu C, Gu Q, Wang J, Zhu S, et al. Abstract
1253: MDM2 inhibitor APG-115 synergizes with CDK4/6 inhibitors
in a patient-derived xenograft model of dedifferentiated
liposarcoma.AACR Annual Meeting 2019. Atlanta, GA, USA March-April, 2019.
[237]
Rudolph D, Weyer-Czernilofsky U, Reschke M, Sykora M, Rinnenthal J, Blake S, et al. Abstract 3197: BI-907828, a novel and potent
MDM2-p53 antagonist, acts synergistically in a triple combination
with anti-PD-1 and anti-LAG-3 antibodies in syngeneic
mouse models of cancer.AACR Annual Meeting 2019. Atlanta,
GA, USA April, 2019.
[246]
Sallman D. Targeting TP53 mutations in myelodysplastic syndromes. The Hematologist: ASH News & Reports 2018; 15(6)
[260]
Meric-Bernstam F, Saleh MN, Infante JR, Goel S, Falchook GS, Shapiro G, et al. Phase I trial of a novel stapled peptide ALRN-
6924 disrupting MDMX- and MDM2-mediated inhibition of WT
p53 in patients with solid tumors and lymphomas.2017 ASCO Annual
Meeting. Chicago, IL, USA (2017).
[265]
Mascarenhas J, Lu M, Virtgaym E, Kosiorek H, Stal M, Sandy L, et al. Open Label Phase I Study of Single Agent Oral RG7388
(idasanutlin) in Patients with Polycythemia Vera and Essential
Thrombocythemia.ASH 2017-59th American Society of Hematology
Annual Meeting and Exposition. Atlanta, USA (2017).
[276]
Welliver M, Van Tine BA, Houghton P, Rudek MA, Pollock RE, Kane JM, et al. MDM2 inhibitor AMG-232 and radiation therapy in treating patients with soft tissue sarcoma with wild-type TP53: A phase IB study (NRG-DT001). J Clin Oncol 2019; 37TPS11076
[278]
Bauer S, Demetri G, Jeay S, Dummer R, Guerreiro N, Tan DS, et al. A phase I, open-label, multi-center, dose escalation study of oral NVP-CGM097, a p53/HDM2-protein-protein interaction inhibitor, in adult patients with selected advanced solid tumors.ESMO 2016 Congress. Copenhagen, Denmark (2016).
[281]
Daver NG, Zhang W, Graydon R, Dawra V, Xie J, Kumar P, et al. A Phase I study of milademetan in combination with quizartinib in patients (pts) with newly diagnosed (ND) or relapsed/refractory (R/R) FLT3-ITD acute myeloid leukemia (AML). J Clin Oncol 2019; 37: TPS7067-7.